Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Search 1,288 verified patient advocacy organizations — the community, research advocates, and family-support groups working on rare diseases.
Kisho provides public health information only — not medical advice. Always consult your healthcare provider.
RDCP:PAG0000245
RDCP:PAG0000246
The XLH Network is a patient support organization for individuals living with X-Linked Hypophosphatemia (XLH), focusing on awareness, education, and community support.
RDCP:PAG0000247
The XLID98 Foundation supports individuals affected by the ultra-rare neurodevelopmental condition XLID98, also known as NEXMIF, KIAA2022, and KIDLIA, and aims to promote awareness and research for treatment.
The XLP Research Trust supports families affected by X-Linked Lymphoproliferative disease and funds research into XLP1 and XIAP.
RDCP:PAG0000248
The YWHAG Research Foundation raises awareness and educates the public about the YWHAG genetic mutation, supporting families affected by this rare neurological disorder.
ZERO TO THREE is dedicated to promoting the healthy development of infants and toddlers through research-based resources, training, and advocacy for policies that support early childhood education and well-being.
The ZMYND11 Treatment Foundation focuses on supporting families affected by the rare ZMYND11 gene disorder and aims to find treatments to improve the function of the ZMYND11 protein and alleviate symptoms.
Run a patient organization? Claim your profile or register a new one.